Skip to main content

Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A

Publication: J Clin Oncol (2004) • Vol 22 • Page 4157-64PMID: 15483026View on PubMed

Purpose

The purpose of this paper was to compare DNA concentrations in serum and plasma from health individuals and those with non-small cell lung cancer (NSCLC). Effects of tube type, cancer stage, remission, leukocyte count and lactate dehydrogenase (LDH) levels were also explored.

Conclusion

Concentrations of cell-free DNA were significantly higher in serum than plasma, and in patients with NSCLC than in healthy controls. Both plasma and serum cell-free DNA concentrations were higher in patients with more advanced tumor stage than those with early-stage tumors. Serum DNA levels decreased when the patient went into remission and plasma DNA concentrations increased with disease progression. Serum DNA concentrations were modestly correlated with leukocyte counts, while plasma DNA concentrations were weakly correlated with LDH levels. The authors report that the yield of cell-free DNA from plasma and serum was comparable between specimens collected in Monovette and Vacutainer tubes.

Studies (1)

Purpose

The purpose of this study was to determine if different collection tube types, cancer stages, remission, leukocyte counts and LDH levels affect cell-free DNA concentrations in plasma and serum from patients with NSCLC and healthy individuals. Blood was obtained from 185 patients with NSCLC and 46 healthy individuals. Additional plasma and serum specimens were obtained at a follow-up visit from 65 and 66 of the original patients, respectively. Of the patients included in this subset, 26 were in remission and 25 had an unchanged  disease status. Plasma and serum were obtained by two centrifugations at 1,500 x g and were stored at -70ºC. DNA was extracted using the QIAamp Blood mini kit and stored at -20ºC until quantification by real-time PCR amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Summary of Findings

The median DNA concentration was approximately 10-fold higher in serum than plasma both in patients with NSCLC (39.8 ng/mL versus 3.7 ng/mL) and healthy controls (12.6 ng/mL versus 1.8 ng/mL). Plasma and serum cell-free DNA concentrations were higher in patients with NCSLC than in healthy individuals (p<0.001, both). Although plasma and serum cell-free DNA concentrations were higher in patients with a more advanced tumor stage than those with early-stage tumors (p=0.003 and p=0.028, respectively), the difference in serum levels due to disease stage was less apparent than in plasma, as levels were elevated even at early stages.  Serum DNA levels decreased when the patient went into remission (p=0.002), but no change was observed with disease progression. In contrast, plasma DNA concentrations were unaffected by remission, but increased with disease progression (p=0.006). Serum, but not plasma DNA concentrations were modestly correlated with leukocyte counts (r=0.529, p<0.001) and thus the authors attribute the higher DNA concentrations in serum than plasma to leukocyte lysis during clotting. Plasma DNA levels were weakly correlated with LDH levels (r=0.261, p=0.009), but a similar correlation was not observed for serum DNA concentrations. The authors report that the yield of cell-free DNA from plasma and serum were comparable between specimens collected in Monovette and Vacutainer tubes.

  • Biospecimens

    FluidBlood
    FluidPlasma
    FluidSerum
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
    Normal
  • Platforms

    DNAReal-time qPCR
    Cell count/volumeHematology/ auto analyzer
    ProteinClinical chemistry/auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionBiomarker level
    1.75-20 G/L leukocytes
    200-950 U/L LDH
    PreaquisitionDiagnosis/ patient condition
    Healthy
    NSCLC
    PreaquisitionPrognostic factor
    Progression
    Remission/No change
    Stage I+II
    Stage III
    Stage IV
    Biospecimen AcquisitionType of collection container/solution
    Monovette
    Vacutainer
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum
    Real-time qPCR SpecificTargeted nucleic acid
    GAPDH